{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:04:18Z","timestamp":1787879058737,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis. This nationwide population-based study aimed to identify disease manifestations, economic burden, and mortality of patients with ATTR-CM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of newly diagnosed patients with ATTR-CM between 2013 and 2018 from the Korean National Health Insurance Service were used, covering the entire population. Patient characteristics included comorbidities, medical procedures, and medication. Healthcare resource utilization and medical costs were observed as measures of the economic burden. The Kaplan\u2013Meier survival curve and years of potential life lost (YPLL) from the general population were estimated for disease burden with ATTR CM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 175 newly diagnosed patients with ATTR-CM were identified. The most common cardiac manifestation was hypertension (51.3%), while the most common non-cardiac manifestation was musculoskeletal disease (68.0%). Mean medical costs at the post-cohort entry date were significantly higher than those at the pre-cohort entry date ($1,864 vs. $400 per patient per month (PPPM), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Of the total medical costs during the study period, the proportion of inpatients cost was 12.9 times higher than the outpatients cost ($1,730 and $134 PPPM, respectively). The median survival time was 3.53\u00a0years from the first diagnosis of ATTR-CM, and the mean (SD) YPLL was 13.0 (7.7).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with ATTR-CM had short survival and high medical costs. To reduce the clinical and economic burdens, carefully examining manifestations of disease in patients can help with early diagnosis and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02425-3","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T16:04:28Z","timestamp":1657901068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-7635","authenticated-orcid":false,"given":"Suk-Chan","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2165-5287","authenticated-orcid":false,"given":"Jin Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-7928","authenticated-orcid":false,"given":"Seung-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-8787","authenticated-orcid":false,"given":"Hye-Lin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-8392","authenticated-orcid":false,"given":"Sun-Hong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7754","authenticated-orcid":false,"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"2","key":"2425_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther"},{"issue":"1","key":"2425_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","volume":"16","author":"D Rintell","year":"2021","unstructured":"Rintell D, Heath D, Braga Mendendez F, Cross E, Cross T, Knobel V, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2425_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300.","journal-title":"Circulation"},{"key":"2425_CR4","unstructured":"Coelho T, Ericzon B-G, Falk R, Grogan D, Ikeda S-i, Maurer M, et al. A guide to transthyretin amyloidosis. Amyloidosis Foundation, Merrill Benson, Mathew Maurer. 2016."},{"issue":"22","key":"2425_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2425_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","volume":"9","author":"AS Hafeez","year":"2020","unstructured":"Hafeez AS, Bavry AA. Diagnosis of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2020;9(1):85\u201395.","journal-title":"Cardiol Ther"},{"issue":"9","key":"2425_CR7","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2425_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"key":"2425_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/CEOR.S207127","volume":"11","author":"TP Quock","year":"2019","unstructured":"Quock TP, Yan T, Tieu R, D\u2019Souza A, Broder MS. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon Outcomes Res. 2019;11:431\u20139.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"2425_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2425_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0168-8510(94)00669-6","volume":"31","author":"JW Peabody","year":"1995","unstructured":"Peabody JW, Lee S-W, Bickel SR. Health for all in the Republic of Korea: one country\u2019s experience with implementing universal health care. Health Policy. 1995;31(1):29\u201342.","journal-title":"Health Policy"},{"issue":"6","key":"2425_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"issue":"10038","key":"2425_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354.","journal-title":"Lancet"},{"issue":"9","key":"2425_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al. Liver Transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847\u201354.","journal-title":"Transplantation"},{"issue":"2","key":"2425_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40120-020-00194-4","volume":"9","author":"SR Reddy","year":"2020","unstructured":"Reddy SR, Chang E, Tarbox MH, Broder MS, Tieu RS, Guthrie S, et al. The clinical and economic burden of newly diagnosed hereditary transthyretin (ATTRv) amyloidosis: a retrospective analysis of claims data. Neurol Ther. 2020;9(2):473\u201382.","journal-title":"Neurol Ther"},{"issue":"6","key":"2425_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2425_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/j.0006-341X.2001.01002.x","volume":"57","author":"H Zhao","year":"2001","unstructured":"Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics. 2001;57(4):1002\u20138.","journal-title":"Biometrics"},{"issue":"7","key":"2425_CR18","doi-asserted-by":"publisher","first-page":"e010744","DOI":"10.1161\/JAHA.118.010744","volume":"8","author":"DG Iyer","year":"2019","unstructured":"Iyer DG, Shah NS, Hastings KG, Hu J, Rodriguez F, Boothroyd DB, et al. Years of potential life lost because of cardiovascular disease in Asian-American subgroups, 2003\u20132012. J Am Heart Assoc. 2019;8(7):e010744.","journal-title":"J Am Heart Assoc"},{"key":"2425_CR19","unstructured":"Korean Statistical Information Service (KOSIS). Complete Life Tables. [cited 2021 May 06]. Available from: https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1B42&conn_path=I2"},{"issue":"12","key":"2425_CR20","doi-asserted-by":"publisher","first-page":"e0208731","DOI":"10.1371\/journal.pone.0208731","volume":"13","author":"H Cho","year":"2018","unstructured":"Cho H, Oh SH, Lee H, Cho HJ, Kang HY. The incremental economic burden of heart failure: a population-based investigation from South Korea. PLoS One. 2018;13(12):e0208731.","journal-title":"PLoS One"},{"issue":"5","key":"2425_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3349\/ymj.2017.58.5.944","volume":"58","author":"H Ku","year":"2017","unstructured":"Ku H, Chung WJ, Lee HY, Yoo BS, Choi JO, Han SW, et al. Healthcare costs for acute hospitalized and chronic heart failure in South Korea: a multi-center retrospective cohort study. Yonsei Med J. 2017;58(5):944\u201353.","journal-title":"Yonsei Med J"},{"issue":"11","key":"2425_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","volume":"27","author":"M Oerlemans","year":"2019","unstructured":"Oerlemans M, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27(11):525\u201336.","journal-title":"Neth Heart J"},{"issue":"3","key":"2425_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","volume":"25","author":"E Bishop","year":"2018","unstructured":"Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018;25(3):174\u20139.","journal-title":"Amyloid"},{"issue":"2","key":"2425_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","volume":"24","author":"N Papoutsidakis","year":"2018","unstructured":"Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis. J Card Fail. 2018;24(2):131\u20133.","journal-title":"J Card Fail"},{"issue":"4","key":"2425_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3988\/jcn.2018.14.4.537","volume":"14","author":"K Choi","year":"2018","unstructured":"Choi K, Seok JM, Kim BJ, Choi YC, Shin HY, Sunwoo IN, et al. Characteristics of South Korean patients with hereditary transthyretin amyloidosis. J Clin Neurol. 2018;14(4):537\u201341.","journal-title":"J Clin Neurol"},{"issue":"2","key":"2425_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222-8 e1.","journal-title":"Am Heart J"},{"issue":"30","key":"2425_CR27","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"key":"2425_CR28","unstructured":"Korea Disease Control. Korea Health Statistics 2019: Korea National Health and Nutrition Examination Survey (KNHANES VIII-1). [cited 2021 December 27]. Available from: https:\/\/health.kdca.go.kr\/healthinfo\/biz\/pblcVis\/main.do"},{"issue":"3","key":"2425_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ejhf.1742","volume":"22","author":"A Milandri","year":"2020","unstructured":"Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22(3):507\u201315.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2425_CR30","first-page":"709","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. J Am Coll Cardiol HF. 2019;7(8):709\u201316.","journal-title":"J Am Coll Cardiol HF"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02425-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T16:07:11Z","timestamp":1657901231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02425-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Sungkyunkwan University, Republic of Korea (SKKU-IRB-2020-02-004). All of the participants\u2019 information was anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}